FGP
FOLD

Freestone Grove Partners’s Amicus Therapeutics FOLD Stock Holding History

Freestone Grove Partners’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-440,846
Closed -$3.47M – 802
2025
Q3 		$3.47M Buy
+440,846
New +$3.14M 0.03% 347

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Freestone Grove Partners's FOLD Position: Q4 2025 in Review

Freestone Grove Partners sold out of Amicus Therapeutics (FOLD) in Q4 2025, closing a stake of 440,846 shares — an estimated $3.47M sold.

Freestone Grove Partners first reported a position in FOLD in Q3 2025 and held it in 1 quarter. The position peaked at $3.47M in Q3 2025. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.

  • Freestone Grove Partners reported no remaining Amicus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 440,846 Amicus Therapeutics shares in Q4 2025, an estimated $3.47M.
  • Freestone Grove Partners first reported a position in Amicus Therapeutics in Q3 2025 and held it in 1 quarter.
  • Freestone Grove Partners's Amicus Therapeutics position peaked at $3.47M in Q3 2025.
  • 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.

Based on Freestone Grove Partners's 13F filing for Q4 2025, filed 17 Feb 2026.